文献速递免疫规划慢病防控与筛查

放射肿瘤患者SARS-CoV-2疫苗接种意愿与体液免疫应答

SARS-CoV-2 vaccination willingness and humoral vaccination response in radiation oncology patients.
PubMed 文献 · Vaccine · 2024-01-20

研究连续纳入某三级放射肿瘤科1142例肿瘤患者,通过标准化访谈评估接种意愿,并在已接种者中于首剂后35天或更晚检测抗SARS-CoV-2 S抗体。接种意愿达90%,97.5%已接种患者可检出抗体;体能状态较差、局部淋巴结转移(N+)、血液系统疾病及弥漫性转移与抗体未阳转相关。

要点

  • 1142例连续纳入的肿瘤患者中,SARS-CoV-2疫苗接种意愿为90%。
  • 已接种患者中97.5%可检出抗SARS-CoV-2 S抗体。
  • 体能状态较差、N+、血液系统疾病及弥漫性转移与抗体未阳转相关。

核心结论

  • SARS-CoV-2疫苗上市后最初数月,肿瘤患者接种意愿高,多数已接种一剂或两剂。
  • 超过97%的已接种患者可检出抗SARS-CoV-2 S抗体滴度。
  • 作者认为数据支持早期识别接种后低体液应答者,并有助于未来肿瘤疫苗试验设计(clinicaltrials.gov标识:NCT04918888)。

研究设计与样本

  • 在三级放射肿瘤科连续招募1142例患者,历时5.5个月。
  • 通过标准化访谈评估SARS-CoV-2疫苗接种意愿。
  • 在已接种患者中,于首剂SARS-CoV-2疫苗后35天或更晚评估针对刺突蛋白的总SARS-CoV-2 S抗体滴度。

主要发现

  • 接种意愿为90%;拒绝最常见原因为:未决定/治疗后可能接种、对疫苗不信任、担心与合并症相互作用。
  • 与较低接种意愿相关的因素为:一般状况较差、年龄较低和女性。
  • 80%的参与者此前已接种疫苗,8%报告既往感染,16%在抗肿瘤治疗期间接种疫苗。
  • 97.5%的已接种患者可检出抗SARS-CoV-2 S抗体。
  • 单变量分析中与未阳转相关的参数为:体能状态较低、局部淋巴结转移(N+)、血液系统疾病和弥漫性转移;所有寡转移性疾病患者均获得阳性抗SARS-CoV-2 S滴度。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: SARS-CoV-2 infection has been and, in some parts, still is a threat to oncologic patients, making it crucial to understand perception of vaccination and immunologic responses in this vulnerable patient segment. SARS-CoV-2 vaccines in relation to malignant disease characteristics and therapies have so far not been studied consecutively in larger oncologic patient populations. This study captures SARS-CoV-2 vaccination willingness and humoral immune response in a large consecutive oncologic patient collective at the beginning of 2021. METHODS: 1142 patients were consecutively recruited over 5.5 months at a tertiary department for radiation oncology and were assessed for vaccination willingness via a standardized interview. In already vaccinated patients total SARS-CoV-2 S antibody titres against the spike protein (Anti-SARS-CoV-2 S) and were evaluated 35 days or later after the first dose of SARS-CoV-2 vaccine. RESULTS: Vaccination willingness was high with a rate of 90 %. The most frequent reasons for rejection were: undecided/potential vaccination after therapy, distrust in the vaccine and fear of interaction with comorbidities. Factors associated with lower vaccination willingness were: worse general condition, lower age and female sex. 80 % of the participants had been previously vaccinated, 8 % reported previous infection and 16 % received vaccination during antineoplastic therapy. In 97.5 % of the vaccinated patients Anti-SARS-CoV-2 S was detected. In a univariable analysis parameters associated with non-conversion were: lower performance status, spread to the local lymphatics (N + ), hematologic disease and diffuse metastases. All patients with oligometastatic disease achieved positive Anti-SARS-CoV-2 S titres. For patients with two vaccinations several risk factors were identified, that were associated with low antibody concentrations. CONCLUSIONS: SARS-CoV-2 vaccination willingness among oncologic patients was high in the first months after its availability, and most patients had already received one or two doses. Over 97 % of vaccinated patients had measurable anti-SARS-CoV-2 S titres. Our data supports early identification of low humoral responders after vaccination and could facilitate the design of future oncologic vaccine trials (clinicaltrials.gov Identifier: NCT04918888).

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Geinitz H, Silberberger E, Spiegl K, et al. SARS-CoV-2 vaccination willingness and humoral vaccination response in radiation oncology patients. Vaccine. 2024. PMID: 38246842. doi:10.1016/j.vaccine.2024.01.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。